公开(公告)号：US12156900B2

公开(公告)日：2024-12-03

申请号：US16764463

申请日：2018-11-16

Applicant: Amgen Inc.

Inventor： Yael Wexler-Cohen ,  William J. Callahan ,  Robert Matthew Fesinmeyer ,  Rahul Rajan Kaushik ,  Sai Chakradhar Padala

IPC: A61K38/18 ,  A61K9/00 ,  A61K47/02 ,  A61K47/14 ,  A61K47/18 ,  A61K47/26 ,  A61K47/34

Abstract: Protein formulations and methods of making and using such formulations are provided herein. The formulation can be an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the formulation comprises a VEGFR-Fc fusion protein, such as aflibercept.

公开(公告)号：US12257343B2

公开(公告)日：2025-03-25

申请号：US16609448

申请日：2018-04-24

Applicant: AMGEN INC.

Inventor： Jian Hua Gu ,  Robert Matthew Fesinmeyer ,  Rulin Qian

IPC: A61K9/08 ,  A61K9/19 ,  A61K47/18 ,  C07K16/24 ,  C07K16/40

Abstract: This invention concerns a series of excipients capable of effectively reducing the viscosity of protein formulations. The viscosity reducing excipients are oligopeptides (e.g., dipeptides, tripeptides) comprising at least one arginine. The peptides may also include basic or acidic or hydrophilic or hydrophobic/aromatic amino acids. An arginine residue may be either at the amino or the carboxyl end of the oligopeptide.